How is BPC-157 Administered While oral solutions and transdermal patches containing BPC-157 have been tested in past trials, the generally preferred route of BPC-157 administration is via injection (IM or subcutaneous)
the relevance this has to SubQ injections is currently unclear but warrants caution in susceptible individuals There is also a theoretical concern, supported by limited animal data, that repeated high-dose glutathione administration may downregulate your own endogenous synthesis pathways (effectively making you dependent on exogenously-administered glutathione over time) Lastly DO NOT use injectable glutathione if you have a history of severe allergic reactions, asthma, or kidney dysfunction without direct supervision from a knowledgeable clinician
The nurse remained in the treatment room for a considerable portion of the total time discussing products, expected results, time until effects felt, and related medical issues because she had time to do so
doi: 10.1038/nrd1066
It can cause joint damage, malformation, incapacity, swelling, and pain in numerous joints (Sharif et al., 2018)
No, it wont
